In the Phase I study (NCT02110355), AMG 232 was investigated for safety and efficacy in combination with MAPK inhibitors (dabrafenib plus trametinib or trametinib alone) in metastatic wild‐type TP53 melanoma. Here, TP53 is linked to melanoma.